Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 14851 - 14875 of 15636 in total
SJG-136 has been used in trials studying the treatment of Recurrent Fallopian Tube Cancer, Secondary Acute Myeloid Leukemia, de Novo Myelodysplastic Syndromes, Recurrent Ovarian Epithelial Cancer, and Secondary Myelodysplastic Syndromes, among others.
Investigational
Matched Description: … Secondary Acute Myeloid Leukemia, de Novo Myelodysplastic Syndromes, Recurrent Ovarian Epithelial Cancer, and
Clinafloxacin is a fluoroquinolone antibacterial currently under research. It has been proven to present good antibiotic properties. However, its approval and release have been halted due to the presence of serious side effects.
Investigational
Matched Description: … However, its approval and release have been halted due to the presence of serious side effects. …
Modimelanotide is under investigation in clinical trial NCT01897519 (A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Surgery).
Investigational
Matched Iupac: … amino-1-[(2S)-2-{[(1S)-1-carbamoyl-2-methylpropyl]carbamoyl}pyrrolidin-1-yl]-1-oxohexan-2-yl]carbamoyl}methyl
Matched Description: … Modimelanotide is under investigation in clinical trial NCT01897519 (A Safety and Efficacy Trial of Multiple …
Experimental
Matched Iupac: … (4R)-4-[(3-butoxy-4-methoxyphenyl)methyl]imidazolidin-2-one …
UK-390,957 has been used in trials studying the treatment of Ejaculation.
Investigational
Matched Iupac: … 3-[(dimethylamino)methyl]-4-[4-(methylsulfanyl)phenoxy]benzene-1-sulfonamide …
Experimental
Matched Iupac: … 4-[(4-tert-butylbenzenesulfonamido)methyl]-N-(pyridin-3-yl)benzamide …
AGI-1096 is a novel oral antioxidant and selective anti-inflammatory agent that is being developed to address the accelerated inflammation of grafted blood vessels, known as transplant arteritis, common in chronic organ transplant rejection.
Investigational
Matched Description: … AGI-1096 is a novel oral antioxidant and selective anti-inflammatory agent that is being developed to …
RPI-78M is being developed for the treatment of multiple sclerosis (MS). Other neurological disorders that may be served by RPI-78M include myasthenia gravis (MG), muscular dystrophy (MD) and amyotrophic lateral sclerosis (ALS).
Investigational
Matched Description: … neurological disorders that may be served by RPI-78M include myasthenia gravis (MG), muscular dystrophy (MD) and
IPH 1101 is a chemically-synthesized structural analog of non-conventional bacterial phosphoantigens which specifically activate the Vγ9Vδ2 T cell subset. IPH 1101 is the most advanced drug candidate of the γδ T cell platform
Investigational
Vitamin A-analog that increases diffusivity of oxygen in aqueous solutions, including plasma.
Investigational
Idraparinux, a synthetic pentasaccharide is an antithrombin-dependent inhibitor of activated factor X. It was developed for the treatment and prevention of thromboembolic events. However, clinical trials have revealed that idraparinux had lead to bleeding. As a result, Sanofi stopped the development of the drug.
Investigational
Matched Iupac: … (2R,3R,4S,5R,6R)-3,4,5-trimethoxy-6-[(sulfooxy)methyl]oxan-2-yl]oxy}oxane-2-carboxylic acid ... ]oxan-3-yl]oxy}oxan-3-yl]oxy}-4,5-bis(sulfooxy)-2-[(sulfooxy)methyl]oxan-3-yl]oxy}-4,5-dimethoxy-3-{[ ... ,3S,4S,5R,6R)-2-carboxy-4,5-dimethoxy-6-{[(2R,3R,4S,5R,6S)-6-methoxy-4,5-bis(sulfooxy)-2-[(sulfooxy)methyl
Matched Description: … It was developed for the treatment and prevention of thromboembolic events. …
Experimental
Matched Iupac: … 2-{5-[amino(iminiumyl)methyl]-6-chloro-1H-indol-2-yl}-6-(cyclopentyloxy)benzen-1-olate …
Experimental
Experimental
Experimental
Displaying drugs 14851 - 14875 of 15636 in total